Home » hepatitis c blood » Recent Articles:

Cirrhosis Causes

March 10, 2010 Liver Disease No Comments

Several processes can lead to cirrhosis.

Alcoholism

Alcoholism particularly endangers the liver. Alcoholic cirrhosis (also sometimes referred to as portal, Laennec’s, nutritional, or micronodular cirrhosis) is the primary cause of cirrhosis in the U.S. It is estimated to be responsible for 44% of deaths from cirrhosis in North America. Some experts believe this estimate is low. One Canadian study found alcohol to be the major contributor to 80% of all cirrhosis deaths.

The relationship between alcohol and cirrhosis is generally as follows:

Alcohol is absorbed from the small intestine, and the blood carries it directly into the liver… Continue reading

Hepatitis C

November 9, 2009 Liver Disease No Comments

Hepatitis C is a disease of the liver that is caused by the hepatitis C virus, or HCV.

Between 15 to 40 percent of people who get hepatitis C are able to fight off the virus during the early, or acute, stage, usually within six months. Between 60 and 85 percent of patients cannot get rid of the virus and develop a long-term, or chronic, hepatitis C infection. People with chronic hepatitis C will have the disease all their lives unless they are successfully treated with antiviral medicines.

[/caption]

Chronic hepatitis C is a serious condition that… Continue reading

ADS:

Featured Content:

ProPSA Measurements In Serum And Tissue Are Associated With Treatment Necessity Among Men Enrolled In Expectant Management For Prostate Cancer

March 19, 2010

UroToday.com – We identified 75 men with available tissue from an initial diagnostic biopsy – of whom 71 had both benign-adjacent and cancer biopsy tissue as well as serum available from the time of diagnosis. Applying the Epstein T1c small tumor criteria, 39 men developed an unfavorable biopsy (Gleason grade6 or 2 cores with cancer or 50% of a core with cancer or a palpable nodule) requiring treatment, while 32 maintained favorable biopsies throughout a median follow-up of 3.7 years…

Go to Source… Continue reading

ProPSA Measurements In Serum And Tissue Are Associated With Treatment Necessity Among Men Enrolled In Expectant Management For Prostate Cancer

March 19, 2010

UroToday.com – We identified 75 men with available tissue from an initial diagnostic biopsy – of whom 71 had both benign-adjacent and cancer biopsy tissue as well as serum available from the time of diagnosis. Applying the Epstein T1c small tumor criteria, 39 men developed an unfavorable biopsy (Gleason grade6 or 2 cores with cancer or 50% of a core with cancer or a palpable nodule) requiring treatment, while 32 maintained favorable biopsies throughout a median follow-up of 3.7 years…

Go to Source… Continue reading

ProPSA Measurements In Serum And Tissue Are Associated With Treatment Necessity Among Men Enrolled In Expectant Management For Prostate Cancer

March 19, 2010

UroToday.com – We identified 75 men with available tissue from an initial diagnostic biopsy – of whom 71 had both benign-adjacent and cancer biopsy tissue as well as serum available from the time of diagnosis. Applying the Epstein T1c small tumor criteria, 39 men developed an unfavorable biopsy (Gleason grade6 or 2 cores with cancer or 50% of a core with cancer or a palpable nodule) requiring treatment, while 32 maintained favorable biopsies throughout a median follow-up of 3.7 years…

Go to Source… Continue reading

ProPSA Measurements In Serum And Tissue Are Associated With Treatment Necessity Among Men Enrolled In Expectant Management For Prostate Cancer

March 19, 2010

UroToday.com – We identified 75 men with available tissue from an initial diagnostic biopsy – of whom 71 had both benign-adjacent and cancer biopsy tissue as well as serum available from the time of diagnosis. Applying the Epstein T1c small tumor criteria, 39 men developed an unfavorable biopsy (Gleason grade6 or 2 cores with cancer or 50% of a core with cancer or a palpable nodule) requiring treatment, while 32 maintained favorable biopsies throughout a median follow-up of 3.7 years…

Go to Source… Continue reading

Acucela And Otsuka Pharmaceutical Receive FDA Fast Track Designation For ACU-4429 In Patients With Dry AMD

March 19, 2010

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD)…

Go to Source… Continue reading

Acucela And Otsuka Pharmaceutical Receive FDA Fast Track Designation For ACU-4429 In Patients With Dry AMD

March 19, 2010

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD)…

Go to Source… Continue reading

Acucela And Otsuka Pharmaceutical Receive FDA Fast Track Designation For ACU-4429 In Patients With Dry AMD

March 19, 2010

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD)…

Go to Source… Continue reading

ProPSA Measurements In Serum And Tissue Are Associated With Treatment Necessity Among Men Enrolled In Expectant Management For Prostate Cancer

March 19, 2010

UroToday.com – We identified 75 men with available tissue from an initial diagnostic biopsy – of whom 71 had both benign-adjacent and cancer biopsy tissue as well as serum available from the time of diagnosis. Applying the Epstein T1c small tumor criteria, 39 men developed an unfavorable biopsy (Gleason grade6 or 2 cores with cancer or 50% of a core with cancer or a palpable nodule) requiring treatment, while 32 maintained favorable biopsies throughout a median follow-up of 3.7 years…

Go to Source… Continue reading

Recent Comments:

  • symptoms of dementia: What's the difference between dementia and Alzheimers? what is the difference? I think my father may be suffering one of these? does anyone know the w...
  • rani: good blog thank 4 the info...
  • JourneyHome: McCarran-Ferguson was originally designed to empower both the federal government and the individual states so that they could act to prevent insurance...
  • Hydro Closet: Hi, I thought I would say you have a wonderful site and rich content. I bookmarked your site and have it in my reader now...looking forward to future ...
  • Allan Ono: Getting more usage from drugs already approved by the FDA for new indications seems like a very good way to expand treatment options without the hyper...